Pfizer Predicts Exubera, Chantix Favorable Reimbursement Despite Delays

Pfizer's Chantix and Exubera are being favorably received by payers in early formulary discussions, Senior VP-Global Pharmaceutical Finance Peter Brandt said during the company's second quarter earnings call July 20